Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Enoxaparin is a type of low molecular weight heparin (LMWH), or anticoagulant, used to
prevent and treat blood clots. Formation of blood clots, or venous thromboemboli (VTE) in
pregnancy can have dangerous and even life-threatening effects on the mother and fetus.
Enoxaparin is the preferred medicine to prevent clotting in pregnant patients who are at risk
for VTE, because it has been studied to be safe and effective in pregnancy without any harms
to the fetus. Although this medication is routinely used and is recommended by several
prominent medical groups, the optimal dosing for prevention of VTE is still unclear. The
range of standardly prescribed dosing regimens of Enoxaparin includes 40mg daily and 1mg/kg
daily, but these two dosing strategies have never been compared in a head to head fashion.